{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:12:58Z","timestamp":1793394778539,"version":"4.5.0"},"reference-count":59,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ear Nose Throat J"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Interventions such as steroids, endoscopic sinus surgery (ESS), biologics, or a combination of these are available for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). However, despite evidence supporting the efficacy of each approach, factors such as timing, cost, side effects, and patient preference need to be considered. The objective of this work was to provide a comparison between current biologics and considerations for each intervention when developing a treatment plan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Recent studies are referenced in a detailed description of current and developing biologics to compare U.S. Food and Drug Administration (FDA) indications, mechanism of actions, notable side effects, dosage, and cost. Considerations for timing of treatment and duration of treatment when analyzing the utility of ESS, biologics, or a combination of both are highlighted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Currently, 3 biologics are FDA-approved for the treatment of inadequately-controlled CRSwNP and 2 biologics demonstrate promise as potential agents. The overall trend in literature suggests that the combination of ESS to relieve polyps and improve medication delivery and biologics to facilitate anti-inflammatory effects is clinically impactful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Evidence to date aligns with current recommendations that biologics are a promising maintenance option for CRSwNP patients who have failed both medical management and complete ESS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/01455613251363018","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T12:18:42Z","timestamp":1753964322000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Considerations for the Use of Biologics in Chronic Rhinosinusitis With Nasal Polyps"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2594-6394","authenticated-orcid":false,"given":"Hannah G.","family":"Luk","sequence":"first","affiliation":[{"name":"School of Medicine, University of Texas Medical Branch, Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6589-2076","authenticated-orcid":false,"given":"Tyler A.","family":"Janz","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Texas Medical Branch, Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrah N.","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Texas Medical Branch, Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7117-7692","authenticated-orcid":false,"given":"Scott A.","family":"Hardison","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Texas Medical Branch, Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22741"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23343"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15074"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21780"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23283"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23282"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22473"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21745"},{"key":"e_1_3_2_11_2","unstructured":"Rosenberg J. FDA approves dupilumab for chronic rhinosinusitis with nasal polyps. AJMC. June 26 2019. Accessed July 28 2025. https:\/\/www.ajmc.com\/view\/fda-approves-dupilumab-for-chronic-rhinosinusitis-with-nasal-polyps"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00097-7"},{"key":"e_1_3_2_13_2","unstructured":"AstraZeneca. Update on US regulatory review of Fasenra in chronic rhinosinusitis with nasal polyps. March 14 2022. Accessed October 13 2024. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/update-on-us-review-of-fasenra-in-nasal-polyps.html"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.030"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330"},{"key":"e_1_3_2_16_2","unstructured":"DUPIXENT\u00ae (dupilumab). Injection instructions & support. 2025. Accessed July 28 2025. https:\/\/www.dupixent.com\/taking-dupixent\/injection-support-center"},{"key":"e_1_3_2_17_2","volume-title":"Dupilumab (Dupixent; Package Insert)","author":"Regeneron","year":"2024","unstructured":"Regeneron. Dupilumab (Dupixent; Package Insert). U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_2_18_2","unstructured":"DUPIXENT\u00ae (dupilumab). Pricing and insurance. 2025. Accessed July 28 2025. https:\/\/www.dupixent.com\/support-savings\/cost-insurance"},{"key":"e_1_3_2_19_2","volume-title":"Omalizumab (Xolair; Package Insert)","author":"Genentech","year":"2024","unstructured":"Genentech. Omalizumab (Xolair; Package Insert). U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_2_20_2","unstructured":"XOLAIR\u00ae (omalizumab). HCP. Xolair. Dosing information for IgE-mediated food allergy patients. 2025. Accessed July 28 2025. https:\/\/www.xolairhcp.com\/food-allergies\/dosing-and-administration\/dosing.html"},{"key":"e_1_3_2_21_2","unstructured":"XOLAIR\u00ae (omalizumab). Xolair. Pricing. Cost. 2025. Accessed July 28 2025. https:\/\/www.xolair.com\/cost.html"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-6-32"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.09.032"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2015.04.014"},{"key":"e_1_3_2_25_2","unstructured":"Stiles L. FDA approves first treatment for eosinophilic granulomatosis with polyangiitis. Pulm Adv. December 14 2017. Accessed July 28 2025. https:\/\/www.pulmonologyadvisor.com\/news\/fda-approves-first-treatment-for-eosinophilic-granulomatosis-with-polyangiitis\/"},{"key":"e_1_3_2_26_2","volume-title":"Mepolizumab (Nucala; Package Insert)","author":"GlaxoSmithKline","year":"2023","unstructured":"GlaxoSmithKline. Mepolizumab (Nucala; Package Insert). U.S. Food and Drug Administration; 2023."},{"key":"e_1_3_2_27_2","unstructured":"GSKForYou. GSK pricing information and details. 2025. Accessed July 28 2025. https:\/\/www.gskforyou.com\/gsk-pricing-information\/"},{"key":"e_1_3_2_28_2","volume-title":"Benralizumab (Fasenra; Package Insert)","author":"AstraZeneca","year":"2024","unstructured":"AstraZeneca. Benralizumab (Fasenra; Package Insert). U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_2_29_2","unstructured":"AstraZeneca. Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis. September 18 2024. Accessed November 24 2024. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.html"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13852"},{"key":"e_1_3_2_31_2","unstructured":"FASENRA\u00ae (benralizumab). Cost and affordability. 2025. Accessed July 28 2025. https:\/\/www.fasenra.com\/cost-affordability.html"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1783242"},{"key":"e_1_3_2_34_2","volume-title":"Tezepelumab (Tezspire; Package Insert)","author":"AstraZeneca","year":"2023","unstructured":"AstraZeneca. Tezepelumab (Tezspire; Package Insert). U.S. Food and Drug Administration; 2023."},{"key":"e_1_3_2_35_2","unstructured":"AstraZeneca. A Multicentre Randomised Double-Blind Parallel-Group Placebo-Controlled Phase 3\u2014Efficacy and Safety Study of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). clinicaltrials.gov. 2024. Accessed November 24 2024. https:\/\/clinicaltrials.gov\/study\/NCT04851964"},{"key":"e_1_3_2_36_2","unstructured":"TEZSPIRE\u00ae (tezepelumab-ekko). Cost and affordability. Subcutaneous injection 210 mg. 2025. Accessed July 28 2025. https:\/\/www.tezspire.com\/en\/home\/cost-affordability.html"},{"key":"e_1_3_2_37_2","volume-title":"Tralokinumab (Adbry; Package Insert)","author":"LEO Pharma, Inc","year":"2023","unstructured":"LEO Pharma, Inc. Tralokinumab (Adbry; Package Insert). U.S. Food and Drug Administration; 2023."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19778"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30184-X"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0889-4"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005"},{"key":"e_1_3_2_42_2","unstructured":"Eli Lilly and Company. FDA approves Lilly\u2019s EBGLYSS\u2122 (lebrikizumab-lbkz) for adults and children 12 years and older with moderate-to-severe atopic dermatitis. September 13 2024. Accessed March 6 2025. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"e_1_3_2_44_2","unstructured":"Research C for DE and. Drug Trials Snapshots: NEMLUVIO. FDA. Published online October 29 2024. Accessed November 25 2024. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-nemluvio"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122753"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1730"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22633"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.13875"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-023-00668-z"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23246"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22851"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23059"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/lio2.523"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.25180"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22864"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.28648"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22936"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23392"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23219"}],"container-title":["Ear, Nose &amp; Throat Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01455613251363018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/01455613251363018","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01455613251363018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:38:58Z","timestamp":1777401538000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/01455613251363018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":59,"alternative-id":["10.1177\/01455613251363018"],"URL":"https:\/\/doi.org\/10.1177\/01455613251363018","relation":{},"ISSN":["0145-5613","1942-7522"],"issn-type":[{"value":"0145-5613","type":"print"},{"value":"1942-7522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"01455613251363018"}}